Israeli Ministry Of Health Approves Remodulin (Treprostinil Sodium) To Treat Pulmonary Arterial Hypertension
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




Israeli Ministry Of Health Approves Remodulin (Treprostinil Sodium) To Treat Pulmonary Arterial Hypertension

RESEARCH TRIANGLE PARK, NC and SILVER SPRING, MD -- November 4, 2002 -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that the Drug Registration Department of the Israeli Ministry of Health has approved Remodulin® (treprostinil sodium) Injection for the treatment of primary pulmonary arterial hypertension and pulmonary arterial hypertension associated with connective tissue disorders. No further clinical studies are required. Approximately 25 patients are currently being treated with Remodulin in Israel.

The Israeli approval represents the second international approval of Remodulin following United States Food and Drug Administration approval on May 21, 2002 and the Canadian Therapeutic Products Directorate approval on October 4, 2002. United Therapeutics has submitted marketing applications for Remodulin in France, Switzerland and Australia, with additional European filings to follow approval in France.

United Therapeutics is a biotechnology company focused on combating cardiovascular, infectious and oncological diseases with unique therapeutic products.


SOURCE: United Therapeutics Corporation


E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities